December 16, 2020
2 min read
The effect of the COVID-19 pandemic has been felt in every aspect of life in 2020, and that includes the dermatology world.
As masks became required throughout the United States to curb the spread of the virus, dermatitis issues began appearing in many. An interview with Heather W. Goff, MD, MPH, regarding this problem and how to solve it was the most-read dermatitis-related news on Healio this year.
Coverage of regulatory actions, study results and meeting news rounded out the top 10 articles of the year.
Q&A: Protective measures may be needed for skin due to mask-wearing during COVID-19 pandemic
The skin of the face can suffer negative consequences from constant covering. Healio spoke with Heather W. Goff, MD, MPH, associate professor of dermatology and Philip J. Eichhorn Professor of Dermatology at UT Southwestern Medical Center, about how to combat skin problems caused by wearing masks. Read more.
FDA approves Dupixent for atopic dermatitis in children
A fully human monoclonal antibody that inhibits the signaling of the interleukin-4 and interleukin-13 proteins, Dupixent (dupilumab) previously was granted breakthrough therapy designation for the treatment of severe AD in children. Read more.
FDA approves Eucrisa for atopic dermatitis in infants
Eucrisa (crisaborole) was previously approved for use in adults and children aged 2 years or older. The supplemental approval makes it the first and only steroid-free, topical prescription medication for patients with AD as young as 3 months of age. Read more.
JAK inhibitors show promise in psoriasis, atopic dermatitis
JAK inhibitors are being studied to treat patients with psoriasis and atopic dermatitis, with many showing promising outcomes, according to a presenter at South Beach Symposium. Read more.
Tapinarof cream shows efficacy in atopic dermatitis
Tapinarof cream was associated with significant improvement as assessed by Investigator Global Assessment in a cohort of adults and adolescents with atopic dermatitis. Read more.
Tape strips identify biomarkers for atopic dermatitis, psoriasis
Twenty D-Squame (CuDerm) tape strips were collected from 20 patients with atopic dermatitis, 20 patients with psoriasis and 20 control subjects. Skin cells from each strip then underwent RNA sequencing and molecular profiling to identify biomarkers for disease. Read more.
EMA recommends approval of baricitinib for atopic dermatitis
The European Medicines Agency has recommended an extension to baricitinib’s indications to include the treatment of moderate to severe atopic dermatitis. Read more.
Roflumilast trial for seborrheic dermatitis completes enrollment
A once-daily topical foam formulation of a phosphodiesterase type 4 inhibitor, roflumilast is being developed to treat inflammatory dermatoses in hair-bearing areas of the body. Read more.
Tralokinumab effective in dermatitis treatment
Tralokinumab 300 mg (Leo Pharma), a fully human monoclonal antibody that neutralizes the IL-13 cytokine, is administered subcutaneously every 2 weeks. Read more.
Lebrikizumab improves EASI, pruritus in adults with atopic dermatitis
The novel interleukin-13 inhibitor lebrikizumab improved skin lesions, pruritis and quality of life among adults with moderate to severe atopic dermatitis, according to data from a phase 2b trial published in JAMA Dermatology. Read more.